Antidepressant Viibryd linked to Pancreatitis?
The attorneys at TheLawFirm.com are investigating potential lawsuits involving Viibryd and acute pancreatitis, as well as pancreatic cancer.
On September 6, 2016, the FDA wrote a letter to Forest Labs about Viibryd. Viibryd was approved by the FDA in 2011 for the treatment of major depressive disorder in adults. By 2014 Viibryd became the third-most prescribed antidepressant.
It now appears that new warnings will be added to the Viibryd label related to a link between the drug and acute pancreatitis. Acute pancreatitis can lead to serious injury and even death. Pancreatitis, especially if it reoccurs, can lead to pancreatic cancer, which is almost always fatal.
Acute pancreatitis occurs when the pancreas suddenly becomes inflamed. The condition usually results in hospitalization, and is fatal about 10% of the time. Victims of acute pancreatitis usually endure severe pain. What is frightening is that up to 25% of patients who develop acute pancreatitis will experience a recurrent episode within the first several years. If acute pancreatitis recurs, the risk of pancreatic cancer is greatly increased. This form of cancer is almost always fatal.
Additionally the attorneys at TheLawFirm.com expect new warnings related to sleep paralysis will also be added to the Viibryd label and prescribing information. Sleep paralysis is a condition in which a person is awake but cannot move or speak. Generally, sleep paralysis occurs upon waking and lasts less than one minute. Although sleep paralysis is a serious condition, and can cause psychological harm in the most severe cases, the condition is generally not life threatening.
TheLawFirm.com is not aware of any lawsuits having been filed yet regarding the link between Viibryd and pancreatitis or pancreatic cancer. However, in December 2016 Forest Laboratories entered into a settlement agreement with the federal government and multiple state Medicaid programs. Forest paid $38 million dollars to settle claims that Forest paid physicians to prescribe Viibryd to their patients. This kind of behavior by the company makes us suspicious. What did they know about the link between Viibryd and pancreatitis and pancreatic cancer before they were forced to warn?
In our experience when new warning labels are added, users of Viibryd will likely come forward with complaints of pancreatitis and pancreatic cancer. We are not sure yet why Viibryd causes problems with the pancreas but this drug is different from other SSRIs in that it is the only one containing a 5HT1A receptor partial agonist. This may be the causative element. Lawyers at TheLawFirm.com are actively investigating and researching this issue.
Our initial research indicates that the highest incidence of Pancreatitis in Viibyrd users may be among women who are 50-59 years old, have been taking the drug for more than one 1 month and also take the medication Gabapentin. An online study we reviewed showed that, of 4,514 people who had side effects while taking Viibryd, 11 had pancreatitis. Given the popularity of Viibryd, we expect these numbers are very low, as not every case of pancreatitis or pancreatic cancer was reported, especially before the FDA warning.
We expect that users of Viibyrd who suffered pancreatitis or pancreatic cancer will now start coming forward.
Viibryd patients who suffer acute pancreatitis or pancreatic cancer will likely incur significant physical, financial and emotional damages due to their illness. While money cannot replace health, filing a Viibryd lawsuit can help victims be compensated for medical bills, pain and suffering, lost wages and emotional distress.
If you, or a loved one, took Viibryd and suffered pancreatitis, or pancreatic cancer, contact the lawyers at TheLawFirm.com immediately for a free consultation.
Click The Link Below To Read The Letter To The Manufacturer Of Viibryd
Talk with aN Attorney now!
TheLawFirm.com’s award winning lawyers have been featured in over 50 radio and television interviews including:
Real lawyers, real results!
no recovery, no fee!